TRUEinvivo is a spinout from the University of Surrey founded by researcher and now clinical scientist Dr. Shakardokht Jafari. She discovered that carefully specified glass beads are excellent detectors of radiation and, specifically, can be used for in-body measurements of radiotherapy to help improve the accuracy of treatments and reduce side effects and other harm caused to 10-25% of patients.ou
Picture:TRUEinvivo® microsilica beads (taken from the TRUEinvivo website)
The company has just had investment success by closing a £430K second seed funding round. Investors include individual angels from the Nexus Investment Ventures Ltd network and from the SyndicateRoom platform members and funds The investment enables the company to develop a pre-production reader product and achieve regulatory approval for its detectors and medical quality management system ahead of a scale-up round in the autumn.
For more information about TRUEinvivo, please do view their website: http://www.trueinvivo.co.uk/